REVIEW ARTICLE

Advances of stem cell based-therapeutic approaches for tendon repair

Lidi Liu a,b,c, Jennifer Hindieh b,c, Daniel J. Leong b,c, Hui B. Sun b,c,*

a Department of Spinal Surgery, The First Hospital of Jilin University, Changchun, China
b Department of Orthopaedic Surgery, Albert Einstein College of Medicine, Bronx, NY, USA
c Department of Radiation Oncology, Albert Einstein College of Medicine, Bronx, NY, USA

Received 8 February 2017; received in revised form 24 March 2017; accepted 24 March 2017
Available online 13 April 2017

KEYWORDS
stem cells; tendinopathy; tendon repair

Summary Tendon injuries are significant clinical problems. Current treatments often result in incomplete repair or healing, which may lead to reduced function and rupture. Stem cell-based therapy is a promising intervention for tendon repair. In this article, we attempt to provide a brief overview on the recent progress in the field, current understanding of the underlying mechanisms of the approach, and the potential of stem cell-based therapies beyond cell implantation. We conclude the review by sharing our viewpoints on the challenges, opportunities, and future directions of this approach.

The translational potential of this article: This paper reviews recent progress on stem cell-based therapeutic approaches for tendon repair, which highlights its translational potential and challenges.

ª 2017 The Authors. Published by Elsevier (Singapore) Pte Ltd on behalf of Chinese Speaking Orthopaedic Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Tendon injuries represent a common clinical problem that affects 30 million people annually [1]. The injuries can occur as a result of trauma, overuse, and aging, and are typically characterised by pain, inflammation, and dysfunction [2–5]. Tendon injuries are currently managed by conservative treatment and surgical intervention [6]. Conservative treatments include injection corticosteroids, over-the-counter nonsteroidal anti-inflammatory drugs, physical therapy, and extracorporeal shock wave therapy [7]. However, tendon healing is usually slow and injured tendons may fail to regain their full function with only conservative treatment [8]. Surgical options are frequently considered for severe acute tendon injuries, such as rupture [9]. Surgical repair with grafts is the current standard treatment for tendon ruptures. There are significant
limitations with this approach, which include continued pain and risk of re-rupture [10], tendon adhesions, formation of scar tissue, ectopic bone formation, and the lack of regeneration of fibrocartilage at the tendon-to-bone junction [8]. Furthermore, these conservative and surgical treatment approaches usually cannot completely restore tendon to their native composition, structure, and mechanical properties. Therefore, there is a critical need for more effective treatments.

The tendon is a connective tissue between muscle and bone [11] that is relatively acellular and avascular consisting of a hierarchical arrangement of collagen fibre bundles [12,13]. Tenocytes are the primary cell type within tendon, and they are responsible for the overall maintenance of tendon [11,14]. Tendon-resident stem cells, termed tendon-derived stem progenitor cells, (TSPCs), were identified by Bi et al. [15]. TSPCs are found in parallel collagen fibrils surrounded by the extracellular matrix, and have a specific niche, which includes extracellular matrix proteins biglycan and fibromodulin, that allows for tenocyte differentiation [15]. The function and fate of TSPCs may decline with age [16,17], under disease conditions (e.g. tendinopathy [18]), or as a result of injury [19].

Advances in stem cell-based therapeutic approaches have shown great potential for tissue repair and regeneration and may be a promising new intervention for tendon repair and regeneration. In this paper, we will primarily review the recent progress on stem cell implantation-based therapy, their therapeutic potential and underlying mechanisms. We will also discuss the potential of stem cell-based approaches beyond cell implantation, such as using stem cell-derived extracellular vesicles (EV) and enhancing endogenous stem homing. Finally, we will conclude the review by sharing our perspectives on the challenges, opportunities, and future directions for stem cell-based approaches for tendon repair and regeneration.

Stem cell-based approaches for tendon repair: an overview

Stem cells for tendon repair

Stem cells can be classified based on their lineage differential potential. Pluripotent stem cells such as embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), can differentiate into any cell in the body. Multipotent stem cells, such as mesenchymal stem cells (MSCs), can develop into more than one cell type, but their differentiation potential is more limited compared to pluripotent cells. ESCs represent a single source of cells that could be used to replace any other cell type in the body which is lost due to damage or disease, and therefore have a significantly broad potential in regenerative medicine, including the repair and regeneration of tendon [20]. Chen et al. demonstrated that human ESCs (hESCs), by differentiating into MSCs (hESC-MSCs) and incorporated into a fibrin gel [21] or onto a knitted silk-collagen sponge scaffold [22], and implanted into a tendon defect can improve tendon structural and mechanical properties in rats. Despite these promising results, whether this therapeutic strategy also benefits patients with chronic tendon injuries such as tendinopathy clinically requires further investigation [23].

Induced pluripotent stem cells (iPSCs) are pluripotent stem cells that can be generated directly from adult cells by introducing four specific genes encoding transcription factors which convert adult somatic cells into pluripotent stem cells [23,24]. The implantation of cells differentiated from iPSCs have negligible immunogenicity [25], which is one reason why iPSCs have become attractive cell sources for tissue repair. Xu et al. [26] first reported iPSC-derived neural crest stem cells (NCSCs) suspended within a fibrin gel and implanted into a rat patellar tendon window defect significantly enhanced tendon healing, compared to that treated with fibrin gel alone. Interestingly, the implantation of the iPSC-NCSCs led to healed wound tissue that exhibited no ectopic bone or cartilage formation during the experimental study for 4 weeks [26]. iPSCs might be a potential source for stem cell-based therapy for tendon repair, but long-term outcome evaluation is critically required. Furthermore, a recent study using equine iPSCs in vitro indicated that although equine iPSCs expressed tendon-associated genes and proteins in two-dimensional differentiation assays, in contrast to equine embryonic stem cells, equine iPSCs failed to generate artificial tendons when cultured in three-dimensional collagen gels [27]. A thorough investigation of the regulatory mechanism that is critical for iPSCs to obtain the reparative and regenerative capacity for tendon repair is required.

MSCs bear the potential for differentiating into a variety of connective tissue cell types including tenocytes. MSCs can be derived from various tissue sources, such as bone marrow [(BM): BM-derived stem cells, (BMSCs)], tendon (TSPCs), and adipose tissue (adipose-derived stem cells, (ADSCs)]. Numerous animal studies have demonstrated that cell-based approaches using MSCs can improve tendon repair (reviewed in [28,29]).

Emerging cell sources for tendon repair include peripheral blood MSC, umbilical cord blood-mesenchymal stem cells (UCB-MSCs), and periodontal ligament cells. For example, injection of peripheral blood MSCs improved histologic features of a diseased tendon in a collagenase-induced tendinopathy model in sheep [30]. Allogeneic UCB-MSCs injected into naturally occurring tendinitis of the superficial digital flexor tendon led to higher performance and strength, as well as improved healing as assessed by ultrasound imaging [31]. Efficacy of UCB-MSCs in improving tendon-bone healing following anterior cruciate ligament reconstruction has also been demonstrated in a rabbit model [32]. Injection of UCB-MSCs into the interface between the bone tunnel and tendon graft improved the histologic appearance in the bone-tendon interface [32]. Furthermore, periodontal ligament-derived stem/progenitor cells, obtained from patients undergoing orthodontic treatment, improved healing of a full-thickness Achilles tendon defect, compared to an untreated defect, and resulted in similar efficacy compared to Achilles tendon-derived cells [33]. While many stem cell types have shown efficacy in animal models, a standard treatment protocol may be required to evaluate and compare the treatment outcome and identify the most promising stem cell option for a specific type of tendon repair.

Many studies only use one type of stem cell. Interestingly, combining multiple stem cells in one treatment led to
an enhanced therapeutic effect. Coculture of BM-MSCs and TSPCs in a 1:1 ratio promoted tenogenic differentiation with increased expression of tenogenic markers and collagen I [34]. Implantation of cell sheets formed using BM-MSCs and TSPCs into a rat patellar tendon window defect resulted in a significant improvement in tendon healing compared to defects treated with BM-MSCs or TSPCs alone [34].

While many stem cell types have been demonstrated to enhance tendon healing, cases with safety concerns and adverse effects have been reported. As shown in BMSCs [35] and ADSCs [36], there is risk of ectopic bone and tumour formation under special circumstances. In both ESCs and iPSCs, there is a risk of teratoma formation after transplantation [37]. Furthermore, obtaining stem cells such as TSPCs may lead to donor site morbidity. Therefore, obtaining a sufficient number of high quality stem cells for clinical application such as TSPCs is challenging. Particular attention should also be paid to stem cell culture conditions. For example, compared to TSPCs cultured under a normoxic condition (20% O2), TSPCs cultured under hypoxic conditions (5% O2) had higher cell proliferation and expression of stem cell markers Oct-4, Nanog, and SSEA-4 [38]. Moreover, TSPCs cultured under a hypoxic condition, seeded onto a decellularised tendon matrix and implanted subcutaneously in nude rats, led to the formation of more extensive tendon-like structures [38], suggesting that a hypoxic condition may be better suited for maintaining the stemness of TSPCs in culture.

**Delivery and promotion of stem cell tenogenic potential**

Appropriate delivery and the promotion of a stem cell’s tenogenic potential during transplantation is critical for stem cell-based tendon repair and regeneration, which remains extremely challenging. Stem cell-based treatments are usually supplemented with other factors, such as pretreating the cells with growth factors, modulating stem cell fate and lineage potential through genetic, epigenetic or physical means, combining treatment with bioactive molecules, or seeding stem cells on functional scaffolds.

Pretreating MSCs with growth factors, such as bone morphogenetic protein-12, to induce tenogenic differentiation prior to stem cell implantation, was reported to enhance repair of an Achilles defect in a rat model [39]. Similarly, a stepwise tenogenic differentiation approach of implanting MSCs that were first cultured with transforming growth factor (TGF)-β1 for 7 days followed by connective tissue growth factor for another 7 days, led to better structural and mechanical properties in a rat patellar tendon repair model [40].

Gene transfer has also been used to overexpress certain transcription factors, such as scleraxis (Scx) [41], early growth response-1 (Egr1) [42], and Smad8 [43], to promote tenogenic differentiation before implantation. For example, the transplantation of Scx-transduced TSPCs promoted healing at the early stage of the tendon repair process in a rat patellar tendon injury model [41]. Injecting MSCs with enforced expression of Egr1 into the site of an Achilles tendon injury in rats increased the formation of tendon-like tissues [42]. Furthermore, implanting MSCs overexpressing Smad8 into a full-thickness Achilles tendon defect in mice led to an improvement in the histologic appearance of the tendon and improved mechanical properties [43].

Together, these growth factor and gene transfer studies suggest that committing stem cells to differentiate towards the tendon lineage prior to implantation may be critical for successful tendon repair. As there is a concern of nontendinous tissue formation with stem cell implantation, it will be critical to extend the duration of these studies to determine whether these strategies could be used to avoid nontendinous tissue differentiation.

Biologics are often used as a supplemental treatment for stem cell-based approaches for tendon repair. For example, platelet-rich plasma (PRP) is an autologous source of various growth factors, including platelet-derived growth factor, TGF-β, insulin-like growth factor, fibroblastic growth factor, and vascular endothelial growth factor [44]. While clinical studies have not clearly demonstrated the efficacy of using PRP alone in enhancing tendon repair [45], the combination of PRP with stem cells may have an enhanced effect. BM-MSCs combined with PRP in fibrin glue, and wrapped around a hamstring tendon enhanced tendon-bone healing compared to PRP alone in a rabbit model of anterior cruciate ligament reconstruction [46]. In dogs with naturally-occurring supraspinatus tendinopathy, injection of ADSCs suspended in PRP into the diseased supraspinatus tendon led to improved pathology as assessed by ultrasound, and functional improvements in gait at 90 days following treatment [47]. While these animal studies suggest that PRP may enhance the reparative ability of stem cells for tendon repair, clinical use of this treatment strategy, to our knowledge, has not yet been reported.

Various scaffolds have been used in tendon repair to provide mechanical support and topographical cues to mimic the native tendon microenvironment, and to enhance tenogenic differentiation of stem cells. For example, aligned silk scaffolds have been demonstrated to induce tenogenic differentiation without overexpression of growth factors [48]. Implantation of TSPC-seeded knitted silk-collagen sponge scaffolds led to improved structural and biomechanical properties compared to controls [49]. In addition to the use of artificial scaffolds, cell sheets have also been experimentally used in tendon regeneration. The cell sheet is a thick layer of confluent cultured cells with its produced extracellular matrix. It has been demonstrated that sheets generated by these MSCs with enforced expression of transcription factor Mohawk (Mkx) promoted tendon repair in a mouse Achilles-tendon defect model [50]. It has also been shown that cell sheets consisting of connective tissue progenitors from hESC lines and foetal tissues surgically implanted into an Achilles tendon defect in nude mice resulted in improved histology and biomechanical properties compared to nontreated mice [51]. Stem cells also showed an enhanced therapeutic outcome when loaded onto a suture during surgery. In a rat Achilles tendon defect model, a suture loaded with MSCs resulted in higher ultimate failure strength compared to the suture-only group [52].
There has been a trend for combining multiple strategies for tendon regeneration. For example, hESCs-MSCs were engineered to overexpress Scx and seeded onto a silk-collagen sponge, prior to implantation in a rat Achilles tendon gap wound model. This three-factor combined treatment led to enhanced tendon repair, compared to injured tendons treated with hESC-MSCs seeded on the silk-collagen sponge [53]. ADSCs treated with a combination of a soluble extract of decellularised tendon extracellular matrix and TGF-β3 treatment, and cultured on an aligned scaffold led to increased Col I matrix synthesis and improved organisation [54]. Together, these studies suggest that guiding MSCs towards tenogenic differentiation and providing a microenvironment that mimics the native tendon tissue are critical to success repair and regeneration of injured or diseased tendons.

Advances in understanding the mechanisms underlying stem cell-based implantation for tendon repair and regeneration

Significant progress has been made in understanding mechanisms underlying the observed therapeutic effect of stem cell-based treatments. For example, fluorescently labelled hESC-MSCs in a fibrin gel that were injected into a patellar wound site were detected 2 weeks after injection, but the number of cells present in the wound declined at 4 weeks [21]. The labelled cells exhibited a spindle-like shape and expressed tendon-specific genes, but not markers of pluripotency [21], suggesting that the injected stem cells differentiated towards the tenogenic lineage. The data further suggest that hESC-MSCs secreted human foetal tendon-specific matrix and differentiation factors at the injury site, which recruited host tendon progenitors that differentiated into tenocytes and produced collagen matrix [21].

In contrast to the hESC-MSC study, MSCs overexpressing EGR1 (MSC-EGR1) injected into the site of tendon injury in rats were not detected 3 weeks after injection [42]. This suggests that the role of the implanted stem cells may be transient. The study further demonstrated that EGR1 increased levels of Tgfβ2 mRNA and TGF-β2 protein in rat tendons grafted with MSC-EGR1, suggesting a potential paracrine mechanism accounting for the therapeutic effects [42].

Consistently, a paracrine effect was also observed in iPSC-NCSCs transplanted into a rat patellar tendon injury [26]. The transplanted iPSC-NCSCs produced foetal tendon-related matrix proteins (collagen XIV, collagen III), stem cell recruitment-related factors (SDF-1, fractalkine), and tenogenic differentiation-related cytokines (e.g., bone morphogenetic protein-12, TGF-β3, basic-fibroblastic growth factor), which together may accelerate the host endogenous repair process [26].

Potential stem cell-based approaches beyond stem cell implantation

Recent studies suggest soluble factors, especially extracellular vesicles (EV), released from stem cells may play a key role in tissue repair. EVs are small membrane vesicles that are secreted by most cells in culture. EVs were first clearly described by Pan and Johnstone in 1983 [55]. EVs include microvesicles, exosomes, and apoptotic bodies. EVs differ both in their physicochemical parameters such as size, density, unique composition of lipids, proteins, and nucleic acids, and in their biogenesis. While microvesicles have a size ranging from 50 to 1000 nm [56], exosomes have diameters of 40–100 nm [57].

EVs, and in particular exosomes, carry various proteins, including those related to intracellular vesicle trafficking, cytoskeletal components, and signal transduction [58]. Exosomes also contain DNA [59], RNA, and microRNA [60]. In recent years, stem cell-derived exosomes have demonstrated the potential to treat many diseases and disorders, including cardiovascular ischaemia [61–63], kidney injury [64], liver fibrotic disease [65], and the healing of cutaneous wounds [66], and may bear potential for tendon repair and regeneration.

It has been demonstrated that stem cells have an innate homing ability due to cytokine receptors present on the cell [67]. Enhancing stem cells to their destination, in particular, to wounded or diseased tendon tissues using specific physical or chemical cues is an area worth intense investigation. It has been reported that delivery of CTGF into a full-thickness rupture of a rat patellar tendon increased the number of endogenous CD146+ stem/progenitor cells within the wound site, and led to a repaired tendon with histological features and structural properties similar to that in native patellar tendons [68].

Challenges, opportunities and future directions

Although significant progress has been made recently, clinical data regarding the therapeutic efficacy of using stem cells to treat tendon injuries and diseases is limited. A recent systematic review [69] identified four clinical trials [70–73] using BM- [71,73] and allogenic adipose-derived stem cells [70,72] for the treatment of tendon disorders (patellar tendinopathy, lateral epicondylar tendinopathy and rotator cuff tears). These four studies found that stem cell treatment led to improved tendon healing, as assessed by imaging, functional outcomes, and pain scores [70–73]. However, only one trial had a control group [71], and all four studies were not blinded, allowing for a high risk of biased results. Therefore, the results should be interpreted with caution [69]. Clearly, many basic and translational studies are needed before stem cell-based therapies can be recommended as a routine clinical treatment for tendon injuries and diseases.

Furthermore, many challenging questions still remain to be addressed, such as: (1) Which sources of stem cells are most promising or bear the best potential to be used? (2) Are there subpopulations of cells among the heterogenous population of MSCs that may bring a more favourable outcome? (3) What type of injuries or diseases require the implantation of stem cells? (4) Can biologics such as stem cell-derived exosomes replicate the therapeutic effect of stem cells in tendon injury and/or disease, and to which extent? Moreover, as there are many significant biological differences between acute or chronic tendon injuries, and the repair mechanisms following these injuries [74],
specific stem-cell therapy approaches may need to be tailored for each particular type of tendon injury. Research to address these questions and issues, may not only advance the basic understanding of the mechanisms underlying the roles stem cells play in tendon repair and regeneration but provide scientific merit and feasibility for stem cell-based approaches such as stem cell implantation, stem cell-derived biologics, and inducing endogenous stem homing. Finally, as a very critical step, it is important to establish standard methodologies and treatment protocols for harvesting, amplification, pretreatment, delivery, and postcell delivery treatment in preclinical studies and in clinical trials.

Conflicts of interest

The authors have no conflicts of interest relevant to this article.

Acknowledgements

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

References

[1] Maffulli N, Wong J, Almekinders LC. Types and epidemiology of tendinopathy. Clin Sports Med 2003;22(4):675–92.
[2] Sharma P, Maffulli N. Tendon injury and tendinopathy: healing and repair. J Bone Jt Surg 2005;87(1):187–202.
[3] Järvinen TA, Kannus P, Maffulli N, Khan KM. Achilles tendon disorders: etiology and epidemiology. Foot Ankle Clin 2005;10(2):255–66.
[4] Raikin SM, Garras DN, Krapchev PV. Achilles tendon injuries in a United States population. Foot Ankle Int 2013;34(4):475–80.
[5] Riley G. Tendinopathy—from basic science to treatment. Nat Clin Pract Rheumatol 2008;4(2):82–9.
[6] Wong J, Barrass V, Maffulli N. Quantitative review of operative and nonoperative management of Achilles tendon ruptures. Am J Sports Med 2002;30(4):565–75.
[7] Andres BM, Murrell GA. Treatment of tendinopathy: what works, what does not, and what is on the horizon. Clin Orthop Relat Res 2008;466(7):1539–54.
[8] Lui PP. Stem cell technology for tendon regeneration: current status, challenges, and future research directions. Stem Cells Cloning 2015;8:163–74.
[9] Burrus MT, Chhabra AB. Distal biceps reconstruction 13 years post-injury. Ther Adv Musculoskelet Dis 2015;7(2):56–9.
[10] Gulati V, Jaggrah M, Al-Nammar SI, Uzoguwe C, Gulati P, Ismail N, et al. Management of achilles tendon injury: a current concepts systematic review. World J Orthop 2015;6(4):380.
[11] Benjamin M, Kaiser E, Milz S. Structure–function relationships in tendons: a review. J Anat 2008;212(3):211–28.
[12] Petersen W, Hohmann G, Stein V, Tillmann B. The blood supply of the posterior tibial tendon. J Bone Jt Surg Br 2002;84(1):141–4.
[13] Kannus P. Structure of the tendon connective tissue. Scand J Med Sci Sports 2000;10(6):312–20.
[14] Kannus P, Jozsa L, Jarvinen M. Basic science of tendons. Principles and practice of orthopaedic sports medicine. Philadelphia: Lippincott Williams and Wilkins; 200021–37.21.
[15] Bi Y, Ehirichou D, Kilts TM, Inkson CA, Embree MC, Sonoyama W. Identification of tendon stem/progenitor cells and the role of the extracellular matrix in their niche. Nat Med 2007;13.
[16] Zhou Z, Akinbiyi T, Xu L, Ramcharan M, Leong DJ, Ros SJ, et al. Tendon-derived stem/progenitor cell aging: defective self-renewal and altered fate. Aging Cell 2010;9(5):911–5.
[17] Hu C, Zhang Y, Tang K, Luo Y, Liu Y, Chen W. Downregulation of CITED2 contributes to TGFbeta-mediated senescence of tendon-derived stem cells. Cell Tissue Res 2017.
[18] Rui YF, Lui PP, Wong YM, Tan Q, Chan KM. Altered fate of tendon-derived stem cells isolated from a failed healing-animal model of tendinopathy. Stem Cells Dev 2013;22(7):1076–85.
[19] Asai S, Otsuru S, Candela ME, Cantley L, Uchibe K, Hofmann TJ, et al. Tendon progenitor cells in injured tendons have strong chondrogenic potential: the CD105-negative subpopulation induces chondrogenic degeneration. Stem Cells 2014;32(12):3266–77.
[20] Hwang NS, Varghese S, Lee HJ, Zhang Z, Ye Z, Bae J, et al. In vivo commitment and functional tissue regeneration using human embryonic stem cell-derived mesenchymal cells. Proc Natl Acad Sci USA 2008;105(52):20641–6.
[21] Chen X, Song XY, Yin Z, Coun XH, Wang LL, Hu H, et al. Stepwise differentiation of human embryonic stem cells promotes tendon regeneration by secreting fetal tendon matrix and differentiation factors. Stem Cells 2009;27(6):1276–87.
[22] Chen JL, Yin Z, Shen WL, Chen X, Heng BC, Zou XH, et al. Efficacy of hESC-MSCs in knitted silk-collagen scaffold for tendon tissue engineering and their roles. Biomaterials 2010;31(36):9438–51.
[23] Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007;318(5858):1917–20.
[24] Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448(7151):313–7.
[25] Araki R, Uda M, Hoki Y, Sunayama M, Nakamura M, Ando S, et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 2013;494(7435):100–4.
[26] Xu W, Wang Y, Liu E, Sun Y, Luo Z, Xu Z, et al. Human iPSC-derived neural crest stem cells promote tendon repair in a rat patellar tendon wound defect model. Tissue Eng Part A 2013;19(21–22):2439–51.
[27] Bavin EP, Smith O, Baird AE, Smith LC, Guest DJ. Equine induced pluripotent stem cells have a reduced tendon differentiation capacity compared to embryonic stem cells. Front Vet Sci 2015;2:1–12.
[28] Docheva D, Muller SA, Majewski M, Evans CH. Biologics for tendon repair. Adv Drug Deliv Rev 2015;84:222–39.
[29] Gulotta LV, Chaudhury S, Wiznza D. Stem cells for augmenting tendon repair. Stem Cells Int 2012:1–7. http://dx.doi.org/10.1155/2012/291431.
[30] Martinello T, Bronzini I, Perazzi A, Testoni S, De Benedictis GM, Negro A, et al. Effects of in vivo applications of peripheral blood-derived mesenchymal stromal cells (PB-MSCs) and platlet-rich plasma (PRP) on experimentally injured deep digital flexor tendons of sheep. J Orthop Res 2013;31(2):306–14.
[31] Van Loon VJ, Scheffer CJ, Genn HJ, Hoogendoorn AC, Greve JW. Clinical follow-up of horses treated with allogeneic equine mesenchymal stem cells derived from umbilical cord blood for different tendon and ligament disorders. Vet Q 2014;34(2):92–7.
[32] Jang KM, Lim HC, Jung WY, Moon SW, Wang JH. Efficacy and safety of human umbilical cord blood-derived mesenchymal
stem cells in anterior cruciate ligament reconstruction of a rabbit model: new strategy to enhance tendon graft healing. Arthroscopy 2015;31(8):1530–9.

[33] Hsieh CF, Alberton P, Loffredo-Verde E, Volkm er E, Pietschmann M, Muller PE, et al. Periodontal ligament cells as alternative source for cell-based therapy of tendon injuries: in vivo study of full-size Achilles tendon defect in a rat model. Eur Cell Mater 2016;32:228–40.

[34] Wu T, Liu Y, Wang B, Sun Y, Xu J, Yuk-Wai LW, et al. The use of cocultured mesenchymal stem cells with tendon-derived stem cells as a better cell source for tendon repair. Tissue Eng Part A 2016;22(19–20):1229–40.

[35] Harris MT, Butler DL, Boivin GP, Florer JB, Schantz EJ, Wenstrup RJ. Mesenchymal stem cells used for rabbit tendon repair can form ectopic bone and express alkaline phosphatase activity in constructs. J Orthop Res 2004;22(5):998–1003.

[36] Martin-Padura I, Gregato G, Marighetti P, Mancuso P, Calleri A, Zhang WY, de Almeida PE, Wu JC. Teratoma formation: a tool for monitoring pluripotency in stem cell research. In: Girard Lisa, editor. StemBook. Cambridge (MA): Harvard Stem Cell Institute; 2008.

[37] Zhang J, Wang JH. Human tendon stem cells better maintain their stemness in hypoxic culture conditions. PLoS One 2013;8(4):e61424.

[38] Lee JY, Zhou Z, Taub PJ, Ramcharan M, Li Y, Akinbiyi T, et al. BMP-12 treatment of adult mesenchymal stem cells in vitro augments tendon-like tissue formation and defect repair in vivo. PLoS One 2011;6(3):e17531.

[39] Yin Z, Guo J, Wu TY, Chen X, Xu LL, Lin SE, et al. Stepwise differentiation of mesenchymal stem cells augments tendon-like tissue formation and defect repair in vivo. Stem Cells Transl Med 2016;5(8):1106–16.

[40] Tan C, Lui PPy, Lee YW, Wang YM. Scx-transduced tendon-derived stem cells (TDSCs) promoted better tendon repair compared to mock-transduced cells in a rat patellar tendon window injury model. PloS One 2014;9(5):e97453.

[41] Guerquin MJ, Charvet B, Nourissat G, Havis E, Ronsin O, Bonnin MA, et al. Transcription factor EGR1 directs tendon differentiation and promotes tendon repair. J Clin Invest 2013;123(8):3564–76.

[42] Pelled G, Snedeker JG, Ben-Arav A, Rigozzi S, Zilberman Y, Kimelman-Bleich N, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 2014;24(6):766–9.

[43] Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. Nat Cell Biol 2007;9(6):654–9.

[44] Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosomes secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010;4(3):214–22.

[45] Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting MeCP2 via miR-22. PLoS One 2014;9(2):e88685.

[46] Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cells 2007;12(2):129–37.

[47] Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 2013;4(2):1–13, Article 34.

[48] Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 2013;22(6):845–54.

[49] Shen W, Chen J, Yin Z, Chen X, Liu H, Heng BC, et al. Allogeneous tendon stem/progenitor cells in silk scaffold for functional shoulder repair. Cell Transpl 2012;21(5):943–58.

[50] Liu H, Zhang C, Zhu S, Lu P, Zhu T, Gong X, et al. Mohawk promotes the tenogenesis of mesenchymal stem cells through activation of the TGFβ signaling pathway. Stem Cells 2015;33(2):443–55.

[51] Cohen S, Leshansky L, Zussman E, Burman M, Srouji S, Livne E, et al. Repair of full-thickness tendon injury using connective tissue progenitors efficiently derived from human embryonic stem cells and fetal tissues. Tissue Eng Part A 2010;16(10):3119–37.

[52] Adams Jr SB, Thorpe MA, Parks BG, Aghazarian G, Allen E, Schon LC. Stem cell-bearing suture improves Achilles tendon healing in a rat model. Foot Ankle Int 2014;35(3):293–9.

[53] Chen X, Yin Z, Chen JL, Liu HH, Shen WL, Fang Z, et al. Scleraxis-overexpressed human embryonic stem cell-derived mesenchymal stem cells for tendon tissue engineering with knitted silk-collagen scaffold. Tissue Eng Part A 2014;20(11–12):1583–92.

[54] Yang G, Rothrauff BB, Lin H, Yu S, Tuan RS. Tendon-derived extracellular matrix enhances transforming growth factor-beta3-induced tenogenic differentiation of human adipose-derived stem cells. Tissue Eng Part A 2017;23(3–4):166–76.

[55] Pan BT, Johnston RM. Fate of the transferrin receptor during maturation of sheep reticulocytes in vitro: selective externalization of the receptor. Cell 1983;33(3):967–78.

[56] Pelled G, Snedeker JG, Ben-Arav A, Rigozzi S, Zilberman Y, Kimelman-Bleich N, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. Cell Res 2014;24(6):766–9.

[57] Lai RC, Arslan F, Lee MM, Sze NS, Choo A, Chen TS, et al. Exosomes secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res 2010;4(3):214–22.

[58] Feng Y, Huang W, Wani M, Yu X, Ashraf M. Ischemic preconditioning potentiates the protective effect of stem cells through secretion of exosomes by targeting MeCP2 via miR-22. PLoS One 2014;9(2):e88685.

[59] Timmers L, Lim SK, Arslan F, Armstrong JS, Hoefer IE, Doevendans PA, et al. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cells 2007;12(2):129–37.

[60] Zhou Y, Xu H, Xu W, Wang B, Wu H, Tao Y, et al. Exosomes released by human umbilical cord mesenchymal stem cells protect against cisplatin-induced renal oxidative stress and apoptosis in vivo and in vitro. Stem Cell Res Ther 2013;4(2):1–13, Article 34.

[61] Li T, Yan Y, Wang B, Qian H, Zhang X, Shen L, et al. Exosomes derived from human umbilical cord mesenchymal stem cells alleviate liver fibrosis. Stem Cells Dev 2013;22(6):845–54.

[62] Zhang J, Guan J, Niu X, Hu G, Guo S, Li Q, et al. Exosomes promote the tenogenesis of mesenchymal stem cells through activation of the TGFβ signaling pathway. Stem Cells 2015;33(2):443–55.
Stem cells for tendon repair

[68] Lee CH, Lee FY, Tarafder S, Kao K, Jun Y, Yang G, et al. Harnessing endogenous stem/progenitor cells for tendon regeneration. J Clin Invest 2015;125(7):2690–701.

[69] Pas HI, Moen MH, Haisma HJ, Winters M. No evidence for the use of stem cell therapy for tendon disorders: a systematic review. Br J Sports Med, Published Online First: 11 January 2017, http://dx.doi.org/10.1136/bjsports-2016-096794.

[70] Ellera Gomes JL, da Silva RC, Silla LM, Abreu MR, Pellanda R. Conventional rotator cuff repair complemented by the aid of mononuclear autologous stem cells. Knee Surg Sports Traumatol Arthrosc 2012;20(2):373–7.

[71] Hernigou P, Flouzat Lachaniette CH, Delambre J, Zilber S, Dufflet P, Chevallier N, et al. Biologic augmentation of rotator cuff repair with mesenchymal stem cells during arthroscopy improves healing and prevents further tears: a case-controlled study. Int Orthop 2014;38(9):1811–8.

[72] Lee SY, Kim W, Lim C, Chung SG. Treatment of lateral epicondylitis by using allogeneic adipose-derived mesenchymal stem cells: a pilot study. Stem Cells 2015;33(10):2995–3005.

[73] Pascual-Garrido C, Rolon A, Makino A. Treatment of chronic patellar tendinopathy with autologous bone marrow stem cells: a 5-year-followup. Stem Cells Int 2012;2012:953510.

[74] Thomopoulos S, Parks WC, Rifkin DB, Derwin KA. Mechanisms of tendon injury and repair. J Orthop Res 2015;33(6):832–9.